Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - PA: Pandemic Preparedness and Health Emergencies Research

Université Laval

$100,000.00

Antiviral Resistance and Benefits of Combination Therapy for Influenza Viruses

EF 2022-23

Résumé
Antiviral therapy is recommended for individuals with severe influenza infections and for those with selected underlying diseases, prone to complications. Thus, currently available antivirals targeting the influenza virus neuraminidase and polymerase enzymes play an important role in the management of influenza infections besides immunisation. However, the emergence of antiviral drug resistance, which is more common in children and immunocompromised patients, may threaten the usefulness of antivirals in the future. The first objective of our proposal is to keep addressing the mechanisms of resistance to anti-influenza drugs with an emphasis on the fitness of drug-resistant mutants. This characteristic includes both the virulence (severity) and transmissibility (by direct contact or by aerosol) of the resistant strains that will be assessed in reconstituted human nasal and bronchial epithelial cells and in a relevant animal model (ferret). In our second objective, we will evaluate combinations of different antiviral agents (neuraminidase and polymerase inhibitors) with or without immune modulators compared to single antiviral therapy in appropriate mouse models with the goal of improving survival and decreasing the emergence of drug-resistant mutants. Our work should provide new insights into the fitness of drug-resistant influenza strains and propose innovative combination therapies for optimal management of this frequent and serious viral disease.
Programme
Project Grant - PA: Pandemic Preparedness and Health Emergencies Research
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
473325
Name
Boivin Guy
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Virology & Viral Pathogenesis
Projecttitle
Antiviral Resistance and Benefits of Combination Therapy for Influenza Viruses
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Pandemic Preparedness and Health Emergencies Research
Keyworddelim
Antiviral; Combination; Ferrets; Immunomodulator; Influenza; Mice; Neuraminidase; Polymerase; Resistance; Therapy
Abstract
Antiviral therapy is recommended for individuals with severe influenza infections and for those with selected underlying diseases, prone to complications. Thus, currently available antivirals targeting the influenza virus neuraminidase and polymerase enzymes play an important role in the management of influenza infections besides immunisation. However, the emergence of antiviral drug resistance, which is more common in children and immunocompromised patients, may threaten the usefulness of antivirals in the future. The first objective of our proposal is to keep addressing the mechanisms of resistance to anti-influenza drugs with an emphasis on the fitness of drug-resistant mutants. This characteristic includes both the virulence (severity) and transmissibility (by direct contact or by aerosol) of the resistant strains that will be assessed in reconstituted human nasal and bronchial epithelial cells and in a relevant animal model (ferret). In our second objective, we will evaluate combinations of different antiviral agents (neuraminidase and polymerase inhibitors) with or without immune modulators compared to single antiviral therapy in appropriate mouse models with the goal of improving survival and decreasing the emergence of drug-resistant mutants. Our work should provide new insights into the fitness of drug-resistant influenza strains and propose innovative combination therapies for optimal management of this frequent and serious viral disease.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Boivin, Guy
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~